Effects of Melatonin on Non-alcoholic fatty liver disease
- Conditions
- onalcoholic fatty liver disease (NAFLD).nonalcoholic steatohepatitis
- Registration Number
- IRCT2016061516123N8
- Lead Sponsor
- Vice Chancellor for Research and Technology, Ahvaz Jundishapur University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
A - Age 18 years and older; with evidence of nonalcoholic fatty liver in ultrasonography with a higher degrees and equal 2 of steatosis; the liver enzyme concentration (alanine aminotransferase or ALT) greater than 1.5 times the highest normal.
b -exclusion criteria: history of alcohol consumption; chronic and acute liver disorders (hepatitis B, C, ...); biliary diseases; autoimmune diseases; cancer; hereditary disorders affecting on liver condition (storage disease of iron, copper, ...); cardiovascular; pulmonary diseases; kidney diseases; pregnancy; breast-feeding; use of contraceptives; hepatotoxic drugs consumption; use of Mineral- multivitamin supplements; weight loss surgery in the past year; weight loss program in 3 month ago; history of hypothyroidism; Cushing's syndrome.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Alanine transaminase. Timepoint: before intervention and after 3 months. Method of measurement: seum level.;Aspartate transaminase. Timepoint: before intervention and after 3 months. Method of measurement: serum level.;Tumor necrosis factor alpha. Timepoint: before intervention and after 3 months. Method of measurement: serum level.;High sensitive C reactive protein. Timepoint: before intervention and after 3 months. Method of measurement: serum level.;Triglyceride. Timepoint: before intervention and after 3 months. Method of measurement: serum level.;Total cholesterol. Timepoint: before intervention and after 3 months. Method of measurement: serum level.;Low density lipoprotein (LDL). Timepoint: before intervention and after 3 months. Method of measurement: serum level.;High density lipoprotein (HDL). Timepoint: before intervention and after 3 months. Method of measurement: serum level.
- Secondary Outcome Measures
Name Time Method Sleep quality. Timepoint: before and 3 months after intervention. Method of measurement: Pittsburgh sleep quality index questionnaire.